Glioblastoma is one of the most aggressive brain tumors in adults, requiring a comprehensive approach that combines surgery, radiation, and medication to slow its progression and manage symptoms, while research continues into innovative treatments that may offer new hope.

Understanding Treatment Goals for Glioblastoma

When someone receives a diagnosis of glioblastoma, the medical team focuses on several important goals. The primary aim is to remove as much of the tumor as safely possible, then use additional treatments to slow down the cancer’s growth and help maintain the best possible quality of life. Because glioblastoma is a grade IV brain tumor – the highest grade, meaning the most aggressive – treatment requires a coordinated effort from neurosurgeons, radiation specialists, and cancer doctors working together.^[1][2]

The treatment approach depends heavily on where the tumor sits in the brain, how large it is, and the patient’s overall health and age. A tumor located near areas that control speech or movement requires extra caution during surgery, while tumors in other locations might be easier to access. Doctors also consider the patient’s ability to tolerate intensive treatments, especially for older individuals.^[5][6]

Medical societies worldwide have established standard treatments based on decades of research and clinical experience. These proven approaches form the foundation of care for glioblastoma patients. At the same time, researchers are actively testing new therapies in clinical trials, searching for methods that might extend survival or improve daily functioning. Some patients choose to participate in these studies as part of their treatment journey, gaining access to experimental drugs and techniques not yet widely available.^[5][12]

It’s important to understand that glioblastoma presents unique challenges. The tumor cells spread into healthy brain tissue like fingers reaching outward, making complete removal impossible. The blood-brain barrier – a protective shield around the brain – blocks many medications from reaching tumor cells. Additionally, the cancer almost always returns even after aggressive treatment, which is why ongoing monitoring and adapting the treatment plan becomes necessary.^[7][8]

Standard Treatment Approaches

Surgery as the First Step

For most patients, treatment begins with surgery to remove as much of the tumor as the neurosurgeon can safely reach. This procedure, called maximal safe resection, aims to take out the bulk of the cancer while protecting critical brain functions like speaking, moving, and thinking. During surgery, doctors may use advanced imaging techniques that help them see the tumor boundaries in real-time, allowing them to remove more cancer while avoiding healthy tissue.^[10][11]

The tissue removed during surgery serves an additional crucial purpose. Laboratory specialists examine it under microscopes and perform genetic tests to confirm the diagnosis and identify specific characteristics of the tumor. These results guide decisions about which additional treatments might work best. For example, doctors look for something called MGMT methylation, which helps predict whether chemotherapy will be particularly effective.^[9][10]

Not every patient can undergo surgery. If the tumor sits deep within the brain or touches areas controlling vital functions, attempting removal might cause severe disabilities. In these cases, doctors might perform a smaller procedure to collect a tissue sample for diagnosis, then move directly to radiation and medication treatments.^[10]

Radiation Therapy

Following surgery, or sometimes as the primary treatment when surgery isn’t possible, radiation therapy targets any remaining cancer cells. The standard approach involves daily treatments, five days per week, for approximately six weeks. Each session lasts only minutes but delivers precisely aimed beams that damage the DNA inside tumor cells, preventing them from multiplying.^[10][11]

Modern radiation techniques use sophisticated imaging to map the exact shape and location of the tumor. This allows radiation beams to concentrate on the cancer while minimizing exposure to surrounding healthy brain tissue. Some centers offer advanced forms like proton beam therapy, which may reduce side effects by delivering radiation more precisely. A recent study showed that using proton therapy with advanced imaging helped older patients with glioblastoma achieve a median survival of 13.1 months, compared to historical averages of only six to nine months with standard treatments.^[13]

During radiation treatment, patients may experience side effects such as fatigue, patchy hair loss where the beams enter the scalp, and skin changes like redness or itching. These effects typically improve within weeks after treatment ends. Some patients also take medications to reduce brain swelling during this period.^[10][11]

Chemotherapy with Temozolomide

The medication temozolomide (also known by the brand name Temodar) has become the standard chemotherapy for glioblastoma. This oral medication works by damaging the genetic material inside cancer cells, preventing them from dividing and growing. Patients take it in pill form at home, making it more convenient than intravenous chemotherapy requiring hospital visits.^[10][11]

The typical treatment schedule involves taking temozolomide daily during the six weeks of radiation therapy. After a break of about four weeks, patients then receive six monthly cycles of a higher dose, taken for five consecutive days each month. Some doctors may extend treatment beyond six cycles if the tumor remains stable and the patient tolerates the medication well.^[11]

Temozolomide can cause side effects including nausea, vomiting, fatigue, and a temporary decrease in blood cell counts. The reduction in white blood cells – which fight infections – and platelets – which help blood clot – requires regular blood testing to ensure levels remain safe. Doctors can adjust doses or temporarily pause treatment if blood counts drop too low. Some patients also receive medications to prevent nausea and antibiotics to protect against certain infections during periods when immunity is reduced.^[10][12]

Supportive Medications

Beyond cancer-directed treatments, doctors prescribe medications to manage symptoms caused by the tumor or its treatment. Corticosteroids such as dexamethasone reduce swelling around the tumor, which can dramatically improve symptoms like headaches and neurological problems. However, long-term steroid use carries risks including weight gain, elevated blood sugar, mood changes, and weakened bones, so doctors try to use the lowest effective dose for the shortest time necessary.^[10]

Many patients develop seizures, requiring anti-epileptic medications to prevent future episodes. These drugs need careful monitoring because they can interact with chemotherapy and other medications. Some patients also need medications for pain, depression, or anxiety, all of which are common and treatable aspects of living with a brain tumor.^[5][12]

Tumor Treating Fields (TTFields)

A newer addition to standard treatment involves a device called Optune, which delivers Tumor Treating Fields or TTFields. This portable device uses adhesive electrode arrays placed on the shaved scalp to deliver low-intensity, alternating electrical fields to the tumor area. These electrical fields disrupt the process of cell division, interfering with cancer cells’ ability to multiply.^[11][12]

Patients wear the device for at least 18 hours daily while carrying out normal activities. Studies have shown that adding TTFields to chemotherapy extended survival by about five months compared to chemotherapy alone. The main side effect is skin irritation where the electrodes attach to the scalp. While the device requires commitment to daily use and lifestyle adjustments, many patients and families find it manageable as part of their treatment routine.^[11][12]

Innovative Treatments in Clinical Trials

Despite the standard treatments described above, glioblastoma remains a devastating disease with limited survival improvements over recent decades. The median survival after diagnosis is approximately 12 to 15 months with current therapies, and fewer than 10% of patients survive five years. This stark reality drives ongoing research into innovative approaches tested through clinical trials.^[5][12]

Immunotherapy Approaches

One of the most promising research directions involves harnessing the body’s immune system to fight cancer. Immunotherapy works on the principle that the immune system can recognize and destroy cancer cells if properly activated. However, glioblastoma creates an environment that suppresses immune responses, making standard immunotherapy less effective than it is for other cancers.^[12]

Researchers are testing checkpoint inhibitors like pembrolizumab, which remove the brakes on immune cells called T cells, allowing them to attack tumors. Early trials combining pembrolizumab with chemotherapy and electrical field therapy showed encouraging results, particularly in patients with larger tumors. In one study, this three-part combination was associated with a 70% increase in overall survival compared to historical controls.^[14]

The electrical fields appear to work synergistically with immunotherapy by attracting more T cells into and around the tumor. These fields create conditions that make the immune system more active and effective against the cancer. Patients with larger, unresected tumors showed particularly strong immune responses, suggesting that having more tumor present may actually provide more targets for the immune system to recognize and attack.^[14]

Clinical trials testing this combination approach typically involve Phase II studies, where researchers evaluate how well the treatment works and continue monitoring for side effects. Patients enrolled in these trials receive the experimental treatment while being closely monitored with regular scans and blood tests. Eligibility often depends on factors like tumor characteristics, previous treatments received, and overall health status.^[12][14]

Targeted Molecular Therapies

Modern understanding of cancer genetics has revealed that glioblastomas contain numerous genetic abnormalities driving their aggressive behavior. Targeted therapy aims to block specific molecular pathways that cancer cells depend on for growth and survival. Researchers have identified three core signaling pathways commonly disrupted in glioblastoma: the p53 pathway, the receptor tyrosine kinase pathway, and others.^[5][12]

One important target is the EGFR (epidermal growth factor receptor), a protein found on cell surfaces that promotes cell growth. Many glioblastomas have abnormalities in EGFR, making it an attractive target for drugs designed to block its activity. Clinical trials are testing various EGFR inhibitors, though results so far have been mixed, highlighting the complexity of the disease.^[5][12]

Other trials focus on drugs that interfere with blood vessel formation around tumors, a process called angiogenesis. Glioblastomas need extensive blood supply networks to fuel their rapid growth. Blocking new blood vessel development can starve tumors of nutrients and oxygen, potentially slowing their progression. However, cancer cells often develop resistance to these drugs over time, limiting their long-term effectiveness.^[12]

These targeted therapy trials typically progress through phases. Phase I studies establish safe dosing in small groups of patients. Phase II trials expand to larger groups to evaluate effectiveness against the tumor while continuing safety monitoring. Phase III trials compare the new drug directly against standard treatment in randomized studies, which provide the strongest evidence of benefit if successful.^[12]

Gene Therapy Innovations

Gene therapy represents a cutting-edge approach that aims to introduce genetic material into tumor cells to kill them or make them more vulnerable to other treatments. Researchers are exploring various strategies, including genes that produce toxic proteins specifically in cancer cells or genes that make tumor cells more visible to the immune system.^[12]

These experimental therapies often require specialized delivery methods to get the therapeutic genes into brain tumor cells. Some approaches use modified viruses as delivery vehicles, while others employ direct injection during surgery. Because gene therapy is relatively new for brain tumors, most clinical trials are in early phases, carefully evaluating safety and determining optimal delivery methods before expanding to larger studies.^[12]

Oncolytic Virus Therapy

Oncolytic viruses are specially engineered viruses designed to selectively infect and kill cancer cells while sparing normal cells. When these viruses enter tumor cells, they multiply and eventually cause the cancer cells to burst open and die. This process also releases tumor antigens that can stimulate an immune response against remaining cancer cells throughout the brain.^[7]

Several oncolytic virus platforms are being tested in glioblastoma clinical trials, with some showing promising early results. These treatments often involve direct injection into the tumor during surgery or through a catheter placed into the tumor bed. Researchers are also exploring combinations of oncolytic viruses with immunotherapy drugs, hoping to create a more powerful anti-tumor effect.^[7]

Finding and Accessing Clinical Trials

Clinical trials for glioblastoma are conducted at specialized centers throughout the United States, Europe, and other regions worldwide. Major cancer centers and university hospitals often have active trial programs. Patients and families can search for available trials through online databases, or work with their oncology team to identify appropriate options based on their specific situation.^[5][12]

Eligibility for trials depends on many factors including tumor characteristics (such as whether it’s newly diagnosed or recurrent), genetic markers found in the tumor, previous treatments received, overall health status, and sometimes age. Some trials specifically recruit patients with newly diagnosed disease who haven’t yet received standard treatment, while others focus on recurrent tumors after standard therapy has failed.^[11][12]

Phase 0 trials represent an innovative approach being explored at some centers. These ultra-short trials test experimental drugs for just a few days before planned surgery, allowing researchers to examine how the drug penetrates the tumor and affects cancer cells. This accelerated timeline provides rapid feedback about promising therapies without delaying standard treatment.^[11]

Most Common Treatment Methods

• Surgical Resection
  • Maximal safe removal of tumor tissue while preserving brain function, typically the first treatment step
  • Use of intraoperative imaging and monitoring to guide extent of resection
  • Tissue collection for diagnosis confirmation and genetic testing
  • Needle biopsy when full resection is not safely possible
• Radiation Therapy
  • Standard external beam radiation delivered daily over six weeks following surgery
  • Proton beam therapy using advanced imaging for more precise targeting in select patients
  • Hypofractionated schedules delivering fewer, larger doses over shorter time periods for older patients
• Chemotherapy
  • Temozolomide (Temodar) oral medication taken daily during radiation and then in monthly cycles
  • Carmustine wafers implanted directly into the tumor cavity during surgery
  • Alternative chemotherapy drugs for recurrent disease
• Tumor Treating Fields (TTFields)
  • Optune device delivering alternating electrical fields through scalp electrodes worn at least 18 hours daily
  • Used in combination with temozolomide chemotherapy for newly diagnosed patients
• Immunotherapy
  • Checkpoint inhibitors like pembrolizumab being tested in clinical trials
  • Combinations with TTFields and chemotherapy showing promising results
  • Strategies to overcome the immunosuppressive tumor environment
• Targeted Molecular Therapy
  • Drugs targeting EGFR and other receptor abnormalities in clinical trials
  • Anti-angiogenesis medications blocking tumor blood vessel formation
  • Treatments selected based on specific genetic changes found in individual tumors
• Gene Therapy and Oncolytic Viruses
  • Experimental introduction of therapeutic genes into tumor cells
  • Engineered viruses designed to selectively infect and destroy cancer cells
  • Approaches to stimulate immune system recognition of tumor cells
• Supportive Care
  • Corticosteroids to reduce brain swelling and control symptoms
  • Anti-epileptic medications to prevent or control seizures
  • Pain management, mood support, and rehabilitation services